Ticker

Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) announces that it was unable to file its annual financial statements, management's discussion and analysis and the required certifications for the year ended October 31, 2025 (the “ Annual Filings ”) on or before the prescribed filing deadline of February 28, 2026 (the “…

Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer   VANCOUVER, BC – TheNewswire - January 29, 2026 / TheNewswire / - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) (“BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen…

Study subject Remains in Complete Response for 3 Years Exceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent Chemotherapy Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in…

VANCOUVER, BC, January 15th,2026/ - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or the "Company") is pleased to provide an update on 1Q2026 initiatives, including collaborations and non-dilutive funding programs. The Company is pleased to announce that it is participating in a Request for Information (RFI) solicitation issued by the US Government's Biomedical Advanced…

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce highly…